Medical device company Dynatronics Corporation (NASDAQ:DYNT) disclosed on Tuesday its net income of USD14,000 for Q2 fiscal 2018 ended 31 December 2017.
This is compared with a net loss of USD95,000 for the quarter ended 31 December 2016.
Net sales of USD18.1m were recorded for the Q2 fiscal 2018 ended 31 December 2017, up 107.5% over net sales of USD8.7m in the same period of the prior year.
Gross profit of USD5.8m was announced for the Q2 fiscal 2018 ended 31 December 2017, a rise of 87.7% versus USD3.1m the same prior year quarter.
The company added that the rise in net sales, gross profit and net income were attributable to its acquisitions of Hausmann and Bird & Cronin in the past year.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government